(株)免疫生物研究所の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|---|---|---|
東証GRT | 医薬品 | 4570/E00986 | Immuno-Biological Laboratories Co.,Ltd. |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|---|---|---|---|---|---|---|---|---|
2017/03/03 | 日証協 | 78,300株 | -3.69% | 0株 | -100% | 229,238株 | -1.25% | 500株 | -78.54% |
2017/02/24 | 日証協 | 81,300株 | +0.74% | 600株 | 0% | 232,138株 | +0.62% | 2,330株 | +133% |
2017/02/17 | 日証協 | 80,700株 | -2.65% | 0株 | 0% | 230,708株 | +15.39% | 1,000株 | -97.04% |
2017/02/10 | 日証協 | 82,900株 | -0.48% | 0株 | -100% | 199,944株 | -8.55% | 33,800株 | +604.17% |
2017/02/03 | 日証協 | 83,300株 | -2.8% | 1,000株 | -72.22% | 218,644株 | +0.96% | 4,800株 | +128.57% |
2017/01/27 | 日証協 | 85,700株 | +6.2% | 3,600株 | -10% | 216,574株 | +1.12% | 2,100株 | -87.66% |
2017/01/20 | 日証協 | 80,700株 | +1.25% | 4,000株 | +344.44% | 214,174株 | -3.38% | 17,013株 | +1316.57% |
2017/01/13 | 日証協 | 79,700株 | -19.9% | 900株 | 0% | 221,667株 | -4.24% | 1,201株 | -64.68% |
2017/01/06 | 日証協 | 99,500株 | -3.68% | 0株 | -100% | 231,471株 | +0.87% | 3,400株 | -73.23% |
2016/12/30 | 日証協 | 103,300株 | -20.35% | 2,200株 | -33.33% | 229,481株 | -1.54% | 12,701株 | +535.05% |
2016/12/22 | 日証協 | 129,700株 | -2.99% | 3,300株 | +230% | 233,080株 | +0.13% | 2,000株 | -80.2% |
2016/12/16 | 日証協 | 133,700株 | -1.55% | 1,000株 | -58.33% | 232,778株 | +2.06% | 10,102株 | +274.15% |
2016/12/09 | 日証協 | 135,800株 | +1.57% | 2,400株 | -22.58% | 228,078株 | +0.27% | 2,700株 | +22.17% |
2016/12/02 | 日証協 | 133,700株 | -8.61% | 3,100株 | +29.17% | 227,468株 | -4.05% | 2,210株 | -7.92% |
2016/11/25 | 日証協 | 146,300株 | +1.32% | 2,400株 | -81.68% | 237,068株 | +0.89% | 2,400株 | -63.09% |
2016/11/18 | 日証協 | 144,400株 | +8.73% | 13,100株 | -4.38% | 234,966株 | +2.71% | 6,502株 | -39.81% |
2016/11/11 | 日証協 | 132,800株 | +9.57% | 13,700株 | +38.38% | 228,763株 | -1.84% | 10,803株 | +89.53% |
2016/11/04 | 日証協 | 121,200株 | +5.94% | 9,900株 | +67.8% | 233,063株 | +1.62% | 5,700株 | -66.29% |
2016/10/28 | 日証協 | 114,400株 | +3.62% | 5,900株 | -15.71% | 229,353株 | +1.64% | 16,910株 | +245.1% |
※株式分割は考慮していませんのでご注意ください。